Prevalence of alcoholic hepatitis and corticosteroid resistance in urban south indians: a cross-sectional study

Main Article Content

Navakanth Raju Ramayanam
Vijayakumar Thangavel Mahalingam
Rajeshan Nanda Amarnath

Keywords

alcoholic hepatitis, corticosteroid resistance, urban south Indians, prevalence

Abstract

Objective: Alcoholic hepatitis (AH) is a severe liver disease caused by excessive alcohol consumption. Urban South Indians face unique socio-demographic characteristics and lifestyle choices that may increase their susceptibility to AH. Understanding the prevalence of AH and factors contributing to corticosteroid resistance in this population is essential for effective management and treatment. Methods: A cross-sectional study was conducted among early-stage AH patients in urban South India. Clinical and demographic data, including alcohol consumption patterns, disease severity, and laboratory parameters, were collected. The Lille Score, a validated tool for assessing corticosteroid response, was used to identify patients resistant to treatment. Statistical analyses, including descriptive and inferential statistics, were performed to determine AH prevalence and explore the association between corticosteroid resistance and clinical variables. Results: A total of 540 AH patients were included in the analysis. The non-responder group exhibited varying levels of different parameters throughout the study, with some improving and others remaining relatively stable. The findings provide insights into the progression and features of AH in non-responder patients over time. Conclusion: This study highlights the burden of AH and identifies factors associated with corticosteroid resistance in urban South Indians. The results have implications for clinical practice and public health interventions, emphasizing the need for early detection and targeted treatment strategies. Further research is warranted to enhance our understanding of AH management in diverse populations and regions.

Abstract 537 | PDF Downloads 197

References

1. Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113(2):175-94. https://doi.org/10.1038/ajg.2017.469
2. O’Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010;51(1):307-28. https://doi.org/10.1002/hep.23258
3. Ramayanam NR, Amarnath RN, Ramasamy MK, et al. Emerging corticosteroid resistance: need for customized medication based on pharmacogenomics profiling. J App Pharm Sci. 2023;13(5):23-32. https://doi.org/10.7324/JAPS.2023.90044
4. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012; 57(2):399-420. https://doi.org/10.1016/j.jhep.2012.04.004
5. Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci. 2007;81(3):177-87. https://doi.org/10.1016/j.lfs.2007.05.005
6. Rao R, Endo I, Obata M, et al. Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. PLOS ONE. 2021; 16(3):e0247417. https://doi.org/10.1371/journal.pone.0247417
7. Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 2011;8(9):491-501.https://doi.org/10.1038/nrgastro.2011.134
8. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790- 800. https://doi.org/10.1056/NEJMoa1105703
9. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007; 45(6):1348-54. https://doi.org/10.1002/hep.21607
10. European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43. https://doi.org/10.1016/j. ejca.2011.12.021
11. Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011; 60(2):255-60. https://doi.org/10.1136/gut.2010.224097
12. Adams S, Juhlin E, Inoue Y. Alcoholic hepatitis: pathogenesis, assessment, and treatment. Clin Liver Dis. 2019;23(4):683-711.
13. Ajmera VH, Terrault NA, Harrison SA, et al. Corticosteroids in severe alcoholic hepatitis: A systematic review and meta-analysis. Hepatol Commun. 2021;5(2):229-42.
14. Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2019;157(5):1084-1095.e3. https://doi.org/10.1053/j.gastro.2014.01.018
15. Amirkalali B, Poustchi H, Keyvani H, et al. Predictive factors for response to corticosteroids in patients with severe alcoholic hepatitis. World J Gastroenterol. 2013;19(44):8212-8.
16. Balakrishnan M, Saraswat VA, Gunjan D, et al. Corticosteroids for alcoholic hepatitis: are the benefits limited to responders? Gastroenterology. 2011;140(4):1178-9.
17. Ramayanam NR, Amarnath RN, Vijayakumar TM. Pharmacogenetic biomarkers and personalized medicine: Upcoming concept in pharmacotherapy. Research Journal of Pharmacy and Technology. 2022;15(9):4289-92.
18. Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut. 2010;59(6):909-14. https://doi.org/10.1136/gut.2006.099226
19. Hamesch K, Mandorfer M, Pereira VM, et al. Corticosteroids for the short-term treatment of alcoholic hepatitis: A network meta-analysis. Cochrane Database Syst Rev. 2019; 2019(3):CD011088.
20. Hartwell LH, Khuri FR. Treatment of alcoholic hepatitis: how to evaluate new therapies. Clin Gastroenterol Hepatol. 2021;19(3):403-5.
21. Kwo PY, Kamath PS. Alcoholic liver disease: clinical practice guidelines by the American Association for the Study of Liver Diseases. Hepatology. 2017;66(6):2276-80.
22. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2015;45(6):1348-54. https://doi.org/10.1002/hep.21607
23. Ramayanam NR, Manickam R, Mahalingam VT, Goh KW, Ardianto C, Ganesan P, Ming LC, Ganesan RM. Functional and Structural Impact of Deleterious Missense Single Nucleotide Polymorphisms in the NR3C1, CYP3A5, and TNF-α Genes: An In Silico Analysis. Biomolecules. 2022 Sep 16;12(9):1307.
24. McCullough AJ, O’Connor JF. Osaimi, A.M. In: Mann KD, Starzl TE, Grieco AM, editors. Transplantation of the liver. Elsevier. 2017;327-44.
25. Michalak A, Rose C, Butterworth RF. Alcoholic liver disease: pathogenesis and new therapeutic targets. Alcohol Alcohol. 2003;38(5):347-54. https://doi.org/10.1053/j.gastro.2011.09.002

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>